The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists.August 25, 2023Check out STAT+Sponsored By SEBASTIEN BOZON/AFP via Getty Images STAT+ | An accidental data release by Roche boosts some hopes for anti-TIGIT cancer immunotherapies The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists. By Jason Mast STAT+ | Drugmakers already bet big on mRNA for cancer. Why is Biden going in, too? Drugmakers already bet big on mRNA for cancer. So why is Biden's new health agency, ARPA-H, going in, too? By Damian Garde and Sarah Owermohle STAT+ | The first complete sequence of Y chromosome offers chance to solve longstanding genetic mysteries The first complete sequence of the Y chromosome offers a boon to research into fertility and genetic risks for diseases. By Megan Molteni More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments